TY  - GEN
AU  - Hata,Aaron N
AU  - Niederst,Matthew J
AU  - Archibald,Hannah L
AU  - Gomez-Caraballo,Maria
AU  - Siddiqui,Faria M
AU  - Mulvey,Hillary E
AU  - Maruvka,Yosef E
AU  - Ji,Fei
AU  - Bhang,Hyo-eun C
AU  - Krishnamurthy Radhakrishna,Viveksagar
AU  - Siravegna,Giulia
AU  - Hu,Haichuan
AU  - Raoof,Sana
AU  - Lockerman,Elizabeth
AU  - Kalsy,Anuj
AU  - Lee,Dana
AU  - Keating,Celina L
AU  - Ruddy,David A
AU  - Damon,Leah J
AU  - Crystal,Adam S
AU  - Costa,Carlotta
AU  - Piotrowska,Zofia
AU  - Bardelli,Alberto
AU  - Iafrate,Anthony J
AU  - Sadreyev,Ruslan I
AU  - Stegmeier,Frank
AU  - Getz,Gad
AU  - Sequist,Lecia V
AU  - Faber,Anthony C
AU  - Engelman,Jeffrey A
TI  - Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
SN  - 1546-170X
PY  - 2016///0719
KW  - Apoptosis
KW  - drug effects
KW  - Blotting, Western
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Cell Cycle
KW  - Cell Line, Tumor
KW  - Cell Survival
KW  - Drug Resistance, Neoplasm
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Gefitinib
KW  - Gene Expression Regulation, Neoplastic
KW  - Humans
KW  - In Vitro Techniques
KW  - Lung Neoplasms
KW  - Mutation
KW  - Protein Kinase Inhibitors
KW  - pharmacology
KW  - Quinazolines
KW  - RNA, Messenger
KW  - Reverse Transcriptase Polymerase Chain Reaction
N1  - Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S
UR  - https://doi.org/10.1038/nm.4040
ER  -